Think Positive: Clovis Confident Of CHMP Okay For Rubraca

The US biotech expects to finally get its PARP inhibitor for ovarian cancer onto the European market in the next few months to compete with rivals AstraZeneca and Tesaro after the CHMP "communicated a positive trend vote" ahead of an opinion being issued next month.

SC1802_Crossed Fingers_351834077_1200.jpg
Fingers crossed: Clovis expects good news from the CHMP in March • Source: Shutterstock

It is looking likely that a third PARP inhibitor will soon be available in Europe to patients with ovarian cancer with Clovis Oncology Inc.'s announcement that it expects a recommendation for approval for Rubraca (rucaparib) from the EU's regulators at the end of next month.

The company says that following a meeting with the European Medicines Agency's Scientific Advisory Group Oncology last week and an...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Anticancer

More from Therapeutic Category